Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 8/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PLG | P00747 | 3/20 | 0.47 |
| ▸ | KLK1 | P06870 | 3/20 | 0.47 |
| ▸ | KLK6 | Q92876 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6381563 | 0.82 | ALOX15 (0.70) | ALOX15NR1H4MAPTRAB9APLG | |
| SCHEMBL13814817 | 0.80 | NR1H4 (0.71) | NR1H4MAPT | |
| SCHEMBL13593311 | 0.80 | PLG (0.67) | ALOX15NR1H4MAPTRAB9APLG | |
| SCHEMBL13814818 | 0.79 | NR1H4 (0.58) | NR1H4MAPTRAB9A | |
| SCHEMBL31661727 | 0.78 | SLC16A3 (0.46) | MAPTRAB9A | |
| SCHEMBL5657531 | 0.78 | SLC16A3 (0.46) | MAPTRAB9A | |
| SCHEMBL5656623 | 0.78 | ALOX15 (0.72) | ALOX15NR1H4MAPTRAB9APLG | |
| SCHEMBL13814819 | 0.78 | SMN1; SMN2 (0.64) | ALOX15NR1H4MAPTRAB9A | |
| SCHEMBL3290446 | 0.78 | PLG (0.56) | ALOX15NR1H4KLKB1PLGKLK1 | |
| SCHEMBL13593307 | 0.78 | P2RX1 (0.66) | ALOX15NR1H4KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106456662-A | Compositions of pentosan polysulfate for oral administration and methods of use thereof | 奥利金制药公司 | 2017-02-22 | — | — | CN | claimed |
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | LE ROUX DANIELLE MARIE (US) | 2026-03-19 | — | — | US | disclosed |
| CN-106456662-A | Compositions of pentosan polysulfate for oral administration and methods of use thereof | 奥利金制药公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7553872-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553872-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7071214-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | VIP, GIPR, SLC10A2 | ALOX15 1799/4885NR1H4 264/4885KLKB1 1002/4885 |
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | ABCB4, ABCB7, ALPP | ALOX15 1253/4885NR1H4 399/4885KLKB1 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.